Complete transglutaminase 2 ablation results in reduced stroke volumes and astrocytes that exhibit increased survival in response to ischemia

Neurobiology of Disease

Volumn 45, Issue 3, 2012, Pages 1042-1050

  Colak, Gozde ^a   Johnson, Gail V W ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Astrocyte; Cell death; Hypoxia; Ischemia; Middle cerebral artery ligation; Neuron; Stroke; Transglutaminase 2

Indexed keywords

PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY LIGATION; ARTICLE; ASTROCYTE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; COCULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; GENETIC CORRELATION; HEART STROKE VOLUME; HYPOGLYCEMIA; HYPOXIA; KNOCKOUT MOUSE; MALE; MARKER GENE; MIDDLE CEREBRAL ARTERY; MOLECULAR INTERACTION; MOUSE; NERVE CELL SURVIVAL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TG2 GENE; WILD TYPE;

ANIMALS; ASTROCYTES; BRAIN; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; FUNCTIONAL LATERALITY; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; GTP-BINDING PROTEINS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; RNA, MESSENGER; STROKE VOLUME; TRANSFECTION; TRANSGLUTAMINASES; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856574714     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.12.023     Document Type: Article

References (73)

1. Ahn J.S., et al. Tissue transglutaminase-induced down-regulation of matrix metalloproteinase-9. Biochem. Biophys. Res. Commun. 2008, 376:743-747.
2. Bailey C.D., et al. Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases. Mol. Neurosci. 2004, 25:493-503.
3. Balklava Z., et al. Analysis of tissue transglutaminase function in the migration of Swiss 3T3 fibroblasts: the active-state conformation of the enzyme does not affect cell motility but is important for its secretion. J. Biol. Chem. 2002, 277:16567-16575.
4. Baranova O., et al. Neuron-specific inactivation of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cerebral ischemia. J. Neurosci. 2007, 27:6320-6332.
5. Beck H., Plate K.H. Angiogenesis after cerebral ischemia. Acta Neuropathol. 2009, 117:481-496.
6. Bondarenko A., et al. Role of Na+-H+ and Na+-Ca2+ exchange in hypoxia-related acute astrocyte death. Glia 2005, 49:143-152.
7. Caccamo D., et al. Antioxidant treatment inhibited glutamate-evoked NF-kappaB activation in primary astroglial cell cultures. Neurotoxicology 2005, 26:915-921.
8. Campisi A., et al. Effect of growth factors and steroids on transglutaminase activity and expression in primary astroglial cell cultures. J. Neurosci. Res. 2008, 86:1297-1305.
9. Campisi A., et al. Glutamate-evoked redox state alterations are involved in tissue transglutaminase upregulation in primary astrocyte cultures. FEBS Lett. 2004, 578:80-84.
10. Chavez J.C., et al. The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. J. Neurosci. 2006, 26:9471-9481.
11. Colak G., et al. Cytosolic guanine nucledotide binding deficient form of transglutaminase 2 (R580a) potentiates cell death in oxygen glucose deprivation. PLoS One 2011, 6:e16665.
12. Colak G., et al. The application of permanent middle cerebral artery ligation in the mouse. J. Vis. Exp. 2011, Jul 25 (53). pii:3039. doi:10.3791/3039.
13. Cramer S.C. An overview of therapies to promote repair of the brain after stroke. Head Neck 2011, Suppl 1:S5-S7.
14. Cunningham L.A., et al. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005, 50:329-339.
15. Dallas M., et al. Hypoxia suppresses glutamate transport in astrocytes. J. Neurosci. 2007, 27:3946-3955.
16. De Laurenzi V., Melino G. Gene disruption of tissue transglutaminase. Mol. Cell. Biol. 2001, 21:148-155.
17. Diaz Z., et al. Astroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disorders. J. Neurochem. 2005, 93:392-402.
18. Downes C.E., Crack P.J. Neural injury following stroke: are Toll-like receptors the link between the immune system and the CNS?. Br. J. Pharmacol. 2010, 160:1872-1888.
19. Escartin C., et al. Neuron-astrocyte interactions in the regulation of brain energy metabolism: a focus on NMR spectroscopy. J. Neurochem. 2006, 99:393-401.
20. Falasca L., et al. Transglutaminase type II is involved in the pathogenesis of endotoxic shock. J. Immunol. 2008, 180:2616-2624.
21. Filiano A.J., et al. Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling. FASEB J. 2008, 22:2662-2675.
22. Filiano A.J., et al. Transglutaminase 2 protects against ischemic stroke. Neurobiol. Dis. 2010, 39:334-343.
23. Fogal B., et al. System x(c)-activity and astrocytes are necessary for interleukin-1 beta-mediated hypoxic neuronal injury. J. Neurosci. 2007, 27:10094-10105.
24. Folbergrova J., et al. Changes in the bioenergetic state of rat hippocampus during 2.5min of ischemia, and prevention of cell damage by cyclosporin A in hyperglycemic subjects. Exp. Brain Res. 1997, 114:44-50.
25. Giffard R.G., et al. Acidosis reduces NMDA receptor activation, glutamate neurotoxicity, and oxygen-glucose deprivation neuronal injury in cortical cultures. Brain Res. 1990, 506:339-342.
26. Griffin M., et al. Transglutaminases: nature's biological glues. Biochem. J. 2002, 368:377-396.
27. Gundemir S., Johnson G.V. Intracellular localization and conformational state of transglutaminase 2: implications for cell death. PLoS One 2009, 4:e6123.
28. Gunnarson E., et al. Identification of a molecular target for glutamate regulation of astrocyte water permeability. Glia 2008, 56:587-596.
29. Hamilton N.B., Attwell D. Do astrocytes really exocytose neurotransmitters?. Nat. Rev. Neurosci. 2010, 11:227-238.
30. Hohenstein B., et al. Vasodilator-stimulated phosphoprotein-deficient mice demonstrate increased platelet activation but improved renal endothelial preservation and regeneration in passive nephrotoxic nephritis. J. Am. Soc. Nephrol. 2005, 16:986-996.
31. Hu J., et al. S100beta induces neuronal cell death through nitric oxide release from astrocytes. J. Neurochem. 1997, 69:2294-2301.
32. Ientile R., et al. Transglutaminase activity and transglutaminase mRNA transcripts in gerbil brain ischemia. Neurosci. Lett. 2004, 363:173-177.
33. Iismaa S.E., et al. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol. Rev. 2009, 89:991-1023.
34. Jang G.Y., et al. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Oncogene 2009, 29:356-367.
35. Kim D.S., et al. Transglutaminase 2 gene ablation protects against renal ischemic injury by blocking constant NF-kappaB activation. Biochem. Biophys. Res. Commun. 2010, 403:479-484.
36. Kim J.Y., et al. BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha. J. Exp. Med. 2004, 199:113-124.
37. Kimelberg H.K. Astrocytic swelling in cerebral ischemia as a possible cause of injury and target for therapy. Glia 2005, 50:389-397.
38. Lee J., et al. Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J. Biol. Chem. 2004, 279:53725-53735.
39. Lin T.N., et al. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke 1993, 24:117-121.
40. Liu R., et al. Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro. J. Neurochem. 2006, 96:1101-1110.
41. Lois C., et al. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002, 295:868-872.
42. Maeda K., et al. Differences in the cerebrovascular anatomy of C57black/6 and SV129 mice. Neuroreport 1998, 9:1317-1319.
43. Milakovic T., et al. Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death. J. Biol. Chem. 2004, 279:8715-8722.
44. Monsonego A., et al. Expression of GTP-dependent and GTP-independent tissue-type transglutaminase in cytokine-treated rat brain astrocytes. J. Biol. Chem. 1997, 272:3724-3732.
45. Nadalutti C., et al. Extracellular transglutaminase 2 has a role in cell adhesion, whereas intracellular transglutaminase 2 is involved in regulation of endothelial cell proliferation and apoptosis. Cell Prolif. 2011, 44:49-58.
46. Nanda N., et al. Targeted inactivation of Gh/tissue transglutaminase II. J. Biol. Chem. 2001, 276:20673-20678.
47. Norenberg M.D., Martinez-Hernandez A. Fine structural localization of glutamine synthetase in astrocytes of rat brain. Brain Res. 1979, 161:303-310.
48. Panickar K.S., Norenberg M.D. Astrocytes in cerebral ischemic injury: morphological and general considerations. Glia 2005, 50:287-298.
49. Parkinson F.E., Xiong W. Stimulus- and cell-type-specific release of purines in cultured rat forebrain astrocytes and neurons. J. Neurochem. 2004, 88:1305-1312.
50. Phillis J.W., O'Regan M.H. Mechanisms of glutamate and aspartate release in the ischemic rat cerebral cortex. Brain Res. 1996, 730:150-164.
51. Raff M.C., Lillien L.E. Differentiation of a bipotential glial progenitor cell: what controls the timing and the choice of developmental pathway?. J. Cell Sci. Suppl. 1988, 10:77-83.
52. Rempe D.A., et al. In cultured astrocytes, p53 and MDM2 do not alter hypoxia-inducible factor-1alpha function regardless of the presence of DNA damage. J. Biol. Chem. 2007, 282:16187-16201.
53. Rius J., et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008, 453:807-811.
54. Rosenstein J.M., Krum J.M. New roles for VEGF in nervous tissue-beyond blood vessels. Exp. Neurol. 2004, 187:246-253.
55. Rossi D.J., et al. Astrocyte metabolism and signaling during brain ischemia. Nat. Neurosci. 2007, 10:1377-1386.
56. Rothstein J.D., et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996, 16:675-686.
57. Saha R.N., Pahan K. Signals for the induction of nitric oxide synthase in astrocytes. Neurochem. Int. 2006, 49:154-163.
58. Schubert P., et al. Protective mechanisms of adenosine in neurons and glial cells. Ann. N. Y. Acad. Sci. 1997, 825:1-10.
59. Silver I.A., et al. Ion homeostasis in brain cells: differences in intracellular ion responses to energy limitation between cultured neurons and glial cells. Neuroscience 1997, 78:589-601.
60. Takano T., et al. Astrocytes and ischemic injury. Stroke 2009, 40:S8-S12.
61. Thanabalasundaram G., et al. Regulation of the blood-brain barrier integrity by pericytes via matrix metalloproteinases mediated activation of vascular endothelial growth factor in vitro. Brain Res. 2010, 1347:1-10.
62. Thomas H., et al. Transglutaminase 6: a protein associated with central nervous system development and motor function. Amino Acids 2011, Oct 8. Electronic publication ahead of print.
63. Thorpe G.H., Kricka L.J. Enhanced chemiluminescent reactions catalyzed by horseradish peroxidase. Methods Enzymol. 1986, 133:331-353.
64. Vangeison G., et al. The good, the bad, and the cell type-specific roles of hypoxia inducible factor-1 alpha in neurons and astrocytes. J. Neurosci. 2008, 28:1988-1993.
65. Verderio E.A., et al. Tissue transglutaminase in normal and abnormal wound healing: review article. Amino Acids 2004, 26:387-404.
66. Verkhratsky A., Toescu E.C. Neuronal-glial networks as substrate for CNS integration. J. Cell. Mol. Med. 2006, 10:826-836.
67. Wardas J. Neuroprotective role of adenosine in the CNS. Pol. J. Pharmacol. 2002, 54:313-326.
68. Wick A., et al. Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J. Neurosci. 2002, 22:6401-6407.
69. Yenari M.A., Lee J.E. Brain 11: what's new in stroke research?. Expert Rev. Neurother. 2011, 11:1235-1237.
70. Zemskov E.A., et al. The role of tissue transglutaminase in cell-matrix interactions. Front. Biosci. 2006, 11:1057-1076.
71. Zhang W., et al. Evidence that hypoxia-inducible factor-1 (HIF-1) mediates transcriptional activation of interleukin-1beta (IL-1beta) in astrocyte cultures. J. Neuroimmunol. 2006, 174:63-73.
72. Zhao B.Q., et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat. Med. 2006, 12:441-445.
73. Zhao Y., Rempe D.A. Targeting astrocytes for stroke therapy. Neurotherapeutics 2010, 7:439-451.